Tharimmune Inc. (THAR) - Total Assets
Based on the latest financial reports, Tharimmune Inc. (THAR) holds total assets worth $7.70 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See THAR net assets for net asset value and shareholders' equity analysis.
Tharimmune Inc. - Total Assets Trend (2019–2024)
This chart illustrates how Tharimmune Inc.'s total assets have evolved over time, based on quarterly financial data.
Tharimmune Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Tharimmune Inc.'s total assets of $7.70 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Tharimmune Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see THAR company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tharimmune Inc.'s current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 95.6% of total assets in 2024, up from 93.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Tharimmune Inc. Competitors by Total Assets
Key competitors of Tharimmune Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Tharimmune Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.98 | 2.30 | 0.11 |
| Quick Ratio | 4.98 | 2.30 | 0.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.15 Million | $2.90 Million | $-2.43 Million |
Tharimmune Inc. - Advanced Valuation Insights
This section examines the relationship between Tharimmune Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 28.74 |
| Latest Market Cap to Assets Ratio | 35.16 |
| Asset Growth Rate (YoY) | -66.0% |
| Total Assets | $3.72 Million |
| Market Capitalization | $130.84 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Tharimmune Inc.'s assets at a significant premium (35.16x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Tharimmune Inc.'s assets decreased by 66.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tharimmune Inc. (2019–2024)
The table below shows the annual total assets of Tharimmune Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.72 Million | -66.00% |
| 2023-12-31 | $10.95 Million | +63.66% |
| 2022-12-31 | $6.69 Million | +975.90% |
| 2021-12-31 | $621.68K | +110.88% |
| 2020-12-31 | $294.80K | +621.11% |
| 2019-12-31 | $40.88K | -- |
About Tharimmune Inc.
Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. It is also involved in the clinical-stage biotech research and development activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. w… Read more